Page Menu

Ann Marshak-Rothstein

 

 

 

 

UMassMed Faculty Page

Inventions: 

Title: AAV2-mediated Gene Delivery of sFasL as a Neuroprotective Therapy in Glaucoma. UMMS16-64; Patent Pending.

  • New AAV therapy facilitates long-term production of sFasLin the retina by intra-vitreal injection with no detrimental effect observed in normal animals. Glaucoma-prone mice were injected either before or after disease onset and both animals were found to have preserved retinal ganglion cells with their axons, which normally results in death with onset of the disease. 

Title: Monoclonal Antibodies Specific for mCherry. UMMS15-10. 

Title: Monoclonal Antibodies that bind Citrullinated Human Fibrinogen. UMMS15-07. 

  • Mouse monoclonal antibodies that recognize the citrullinated form of human fibrinogen. 

Title: Dual Specific Binding Proteins Directed Against Immune Cell Receptors and Autoantigens. UMMS14-75; Patent Pending. 

Title: Monoclonal Antibodies Specific for Streptavidin. UMMS14-67.

Title: BCR Adapter lgM (BCRAM) for the BCR/TLR Delivery of Autoantigens to Polyclonal Murine and Human B Cell Populations. UMMS13-65; Patent Pending.

  • This technology provides a model for autoantigen activation of B cells that can be used to research and treat the development/progression of autoimmune diseases, such as systemic lupus erythematosus (SLE).  This novel research tool enables the identification of suitable drug targets and provides methods for production of autoantigens.  Specifically, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by Toll-like receptor activation. 

 

Innovation TopicsGene TherapyAAVGlaucomaOphthalmologyResearch ToolsAntibodyBiologicsAutoimmune diseaseRheumatoid Arthritis (RA)Sjogren's Syndrome (SS)Systemic Lupus Erythematosus (SLE)Progressive Systemic Sclerosis (PSS)Mixed Connective Tissue Disease (MCTD)StreptavidinLupus